[1] |
Dimaras H, Corson TW, Cobrinik D, et al. Retinoblastoma[J]. Nat Rev Dis Primers, 2015, 1: 15021.
|
[2] |
Gao YJ, Qian J, Yue H, et al. Clinical characteristics and treatment outcome of children with intraocular retinoblastoma: a report from a Chinese cooperative group[J]. Pediatr Blood Cancer, 2011, 57 (7): 1113-1116.
|
[3] |
Zhou CD, Wen XY, Ding Y, et al. Eye-preserving therapies for advanced retinoblastoma: a multicenter cohort of 1678 patients in China[J]. Ophthalmology, 2022, 129(2): 209-219.
|
[4] |
Luo YX, Zhou CD, He FL, et al. Contemporary update of retinoblastoma in China: three-decade changes in epidemiology, clinical features, treatments, and outcomes[J]. Am J Ophthalmol, 2022, 236: 193-203.
|
[5] |
MacCarthy A, Draper GJ, Steliarova-Foucher E, et al. Retinoblastoma incidence and survival in European children (1978-1997). Report from the automated childhood cancer information system project[J]. Eur J Cancer, 2006, 42(13): 2092-2102.
|
[6] |
Canadian Retinoblastoma Society. National retinoblastoma strategy Canadian guidelines for care: stratégie thérapeutique du rétinoblastome guide clinique canadien[J]. Can J Ophthalmol, 2009, 44 Suppl 2: S1-88.
|
[7] |
Dimaras H, Kimani K, Dimba EA, et al. Retinoblastoma[J]. Lancet, 2012, 379(9824): 1436-1446.
|
[8] |
Weichert W, Kristiansen G, Winzer KJ, et al. Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications[J]. Virchows Arch, 2005, 446(4): 442-450.
|
[9] |
Zhang J, Benavente CA, McEvoy J, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses[J]. Nature, 2012, 481(7381): 329-334.
|
[10] |
Afshar AR, Pekmezci M, Bloomer MM, et al. Next-generation sequencing of retinoblastoma identifies pathogenic alterations beyond RB1 inactivation that correlate with aggressive histopathologic features[J]. Ophthalmology, 2020, 127(6): 804-813.
|
[11] |
He MY, An Y, Gao YJ, et al. Screening of RB1 gene mutations in Chinese patients with retinoblastoma and preliminary exploration of genotype-phenotype correlations[J]. Mol Vis, 2014, 20: 545-552.
|
[12] |
Cheng GY, Wang YC, Bin L, et al. Genetic and epigenetic profile of retinoblastoma in a Chinese population: analysis of 47 patients[J]. Asia Pac J Ophthalmol (Phila), 2013, 2(6): 414-417.
|
[13] |
Abidi O, Knari S, Sefri H, et al. Mutational analysis of the RB1 gene in Moroccan patients with retinoblastoma[J]. Mol Vis, 2011, 17: 3541-3547.
|
[14] |
Li LT, Li HB, Zhang J, et al. Five novel RB1 gene mutations and genotype-phenotype correlations in Chinese children with retinoblastoma[J]. Int Ophthalmol, 2022, 42(11): 3421-3430.
|
[15] |
Nguyen HH, Nguyen HTT, Vu NP, et al. Mutational screening of germline RB1 gene in Vietnamese patients with retinoblastoma reveals three novel mutations[J]. Mol Vis, 2018, 24: 231-238.
|
[16] |
Rojanaporn D, Boontawon T, Chareonsirisuthigul T, et al. Spectrum of germline RB1 mutations and clinical manifestations in retinoblastoma patients from Thailand[J]. Mol Vis, 2018, 24: 778-788.
|
[17] |
Kiet NC, Khuong LT, Minh DD, et al. Spectrum of mutations in the RB1 gene in Vietnamese patients with retinoblastoma[J]. Mol Vis, 2019, 25: 215-221.
|
[18] |
Mohd Khalid MKN, Yakob Y, Md Yasin R, et al. Spectrum of germ-line RB1 gene mutations in Malaysian patients with retinoblastoma[J]. Mol Vis, 2015, 21: 1185-1190.
|
[19] |
Parma D, Ferrer M, Luce L, et al. RB1 gene mutations in Argentine retinoblastoma patients. Implications for genetic counseling[J]. PLoS One, 2017, 12(12): e0189736.
|
[20] |
Helmke C, Becker S, Strebhardt K. The role of plk3 in oncogenesis[J]. Oncogene, 2016, 35(2): 135-147.
|
[21] |
Lee KS, Burke TR Jr, Park JE, et al. Recent advances and new strategies in targeting plk1 for anticancer therapy[J]. Trends Pharmacol Sci, 2015, 36(12): 858-877.
|
[22] |
do Carmo Avides M, Tavares A, Glover DM. Polo kinase and Asp are needed to promote the mitotic organizing activity of centrosomes[J]. Nat Cell Biol, 2001, 3(4): 421-424.
|
[23] |
Zitouni S, Nabais C, Jana SC, et al. Polo-like kinases: structural variations lead to multiple functions[J]. Nat Rev Mol Cell Biol, 2014, 15(7): 433-452.
|
[24] |
Degenhardt Y, Lampkin T. Targeting Polo-like kinase in cancer therapy[J]. Clin Cancer Res, 2010, 16(2): 384-389.
|
[25] |
Singh L, Pushker N, Sen S, et al. Prognostic significance of Polo-like kinases in retinoblastoma: correlation with patient outcome, clinical and histopathological parameters[J]. Clin Exp Ophthalmol, 2015, 43(6): 550-557.
|
[26] |
Stacey AW, Bowman R, Foster A, et al. Incidence of retinoblastoma has increased: results from 40 European countries[J]. Ophthalmology, 2021, 128(9): 1369-1371.
|
[27] |
Kooi IE, Mol BM, Massink MP, et al. Somatic genomic alterations in retinoblastoma beyond RB1 are rare and limited to copy number changes[J]. Sci Rep, 2016, 6: 25264.
|
[28] |
Winkles JA, Alberts GF. Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues[J]. Oncogene, 2005, 24(2): 260-266.
|
[29] |
Chopra P, Sethi G, Dastidar SG, et al. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics[J]. Expert Opin Investig Drugs, 2010, 19(1): 27-43.
|
[30] |
Andrysik Z, Bernstein WZ, Deng L, et al. The novel mouse Polo-like kinase 5 responds to DNA damage and localizes in the nucleolus[J]. Nucleic Acids Res, 2010, 38(9): 2931-2943.
|
[31] |
Vaughan CA, Singh S, Subler MA, et al. The oncogenicity of tumor-derived mutant p53 is enhanced by the recruitment of PLK3[J]. Nat Commun, 2021, 12(1): 704.
|
[32] |
Thangavel C, Boopathi E, Ciment S, et al. The retinoblastoma tumor suppressor modulates DNA repair and radioresponsiveness[J]. Clin Cancer Res, 2014, 20(21): 5468-5482.
|
[33] |
Pellegrino R, Calvisi DF, Ladu S, et al. Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma[J]. Hepatology, 2010, 51(3): 857-868.
|
[34] |
Weichert W, Denkert C, Schmidt M, et al. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma[J]. Br J Cancer, 2004, 90: 815-821.
|